Corneal Cross-linking
If you suffer from keratoconus, your wait for progressive treatment is finally over. The FDA has approved corneal collagen cross-linking (CXL) to strengthen weak corneas caused by keratoconus – and ultimately save vision. It may also reduce the need for corneal transplants for some patients.
Schein Ernst Mishra Eye is excited to offer keratoconus patients corneal cross-linking in Harrisburg.
How CXL Works
By applying a riboflavin solution (a form of vitamin-B2) to the eye, followed by ultraviolet A light exposure, this procedure can make the cornea stronger, more stable and able to hold its shape. There are two types of CXL:
- Epithelium off: the thin outer layer of the eye’s surface is removed and liquid riboflavin eye drops are applied
- Epithelium on (transepithelial): liquid riboflavin eye drops are applied directly to the eye, without removing the thin outer layer of the eye’s surface
This process increases the amount of collagen cross-links in the cornea. A single treatment may be all that is needed to improve vision.
While not a cure for the disease, this keratoconus treatment has been effective in slowing the progression of the disease and helping preserve vision. Some patients may still need to wear prescription glasses or contact lenses to achieve their best vision possible.
If you have been diagnosed with keratoconus, contact us today to schedule an eye exam with our keratoconus doctors in Harrisburg and learn about this innovative treatment option.
